Fig. 2: ROC curves for ClarityDX Prostate, prostate cancer risk calculators, % Free PSA, and PSA when predicting csPCa defined as grade group ≥2 prostate cancer.

ROC curves in the training cohort (a) and validation cohort (b). AUC values were compared using DeLong’s method. ClarityDX Prostate had significantly greater AUC values than all other tested risk calculators and PSA for predicting prostate cancer and csPCa in the training and validation cohorts. Sen: sensitivity, Spe: specificity.